Lymphoma Clinical Trial
Official title:
Diffusion-weighted Magnetic Resonance Imaging in Post Therapy Evaluation of Patients With Malignant Lymphoma: Comparison With 2-deoxy-2-fluoro-D-glucose-positron Emission Tomography/Computed Tomography
- The goal of this study is to determine the feasibility of the diffusion weighted
Magnetic Resonance Imaging in the evaluation of the treatment response in patients with
malignant lymphoma.
- The investigator's objective is to compare the changes of mean Apparent Diffusion
Coefficient value of the tumor with the changes of maximum Standardized Uptake Value of
the tumor in positron Emission Tomography Computed Tomography in both pre and post
therapy status .
Lymphomas are the malignant tumors of lymph nodes and considered as one of the most common
primary hematopoietic malignancy. Multi slice computed tomography is the most readily
available and most commonly used tool for staging lymphoma. But it has multiple limitations
in diagnosis of lymphoma as the recognition of lymph node involvement is based only on the
size of the lymph node without any metabolic information .
The tumors rely on glucose as their substrate for energy production and replication, this
metabolic information can be obtained from the 2-deoxy-2-fluoro-D-glucose Among the positron
Emission Tomography Computed Tomography parameters, standardized uptake value is currently
the most commonly used semi-quantitative index of 2-deoxy-2-fluoro-D-glucose metabolic rate.
standardized uptake value reflects tumor glucose metabolism, and is commonly represented by
the maximum standardized uptake value .2-deoxy-2-fluoro-D-glucose positron Emission
Tomography Computed Tomography has been shown to be more accurate for the evaluation of the
extent of disease and treatment response by providing these metabolic information in patients
with malignant lymphoma .
2-deoxy-2-fluoro-D-glucose positron Emission Tomography Computed Tomography , with the
advantage of being able to perform whole-body detection of malignant lesions, is considered
to be the current standard of practice for the management of lymphomas; however, positron
Emission Tomography Computed Tomography is expensive, time-consuming, involves exposure to
ionizing radiation and is not widely available because it requires large and expensive
equipment . In contrast, Magnetic Resonance Imaging provides excellent tissue contrast, high
spatial resolution, detailed morphological information without the use of ionizing radiation
. Diffusion-weighted Magnetic Resonance Imaging is a noninvasive technique allows
visualization of diffusion properties of water molecules in biologic tissues. .
A supplemental tool in Diffusion-weighted imaging is the apparent diffusion coefficient map ,
acquired by post-processing of the obtained Diffusion-weighted images . apparent diffusion
coefficient allows for quantitative definition of diffusion parameters (in mm2/sec) .
Diffusion-weighted images with apparent diffusion coefficient mapping could provide useful
functional information regarding the characterization of lymphomas .Because of their high
cellularity and high nuclear-to-cytoplasm ratio .
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540340 -
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
|
Phase 1 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT00001512 -
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Completed |
NCT01410630 -
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
|
||
Active, not recruiting |
NCT04270266 -
Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT01949883 -
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma
|
Phase 1 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Recruiting |
NCT05019976 -
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
|
N/A | |
Completed |
NCT04434937 -
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
|
Phase 2 | |
Completed |
NCT01855750 -
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
|
Phase 3 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT00775268 -
18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03936465 -
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
|
Phase 1 |